Pharmaceutical - Respiratory and Pulmonary

Filter

Current filters:

Respiratory and Pulmonary

Popular Filters

1 to 25 of 316 results

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

ALK Abello reports positive financials for third quarter with sales up 3%

ALK Abello reports positive financials for third quarter with sales up 3%

14-11-2014

Denmark-based allergy specialist ALK Abello has reported positive results for the third quarter of 2014.

ALK AbelloDenmarkFinancialGrazaxPharmaceuticalRespiratory and Pulmonary

GlaxoSmithKline invests in Australia plant expansion

14-11-2014

UK pharma major GlaxoSmithKline’s Australian subsidiary today announced it will be investing A$31 million…

AustraliaFinancialGlaxoSmithKlinePharmaceuticalProductionRespiratory and PulmonaryVentolin HFA

GSK COPD survey shows many sufferers underestimate the severity of their condition

GSK COPD survey shows many sufferers underestimate the severity of their condition

12-11-2014

UK pharma major GlaxoSmithKline has conducted a global survey of people living with chronic obstructive…

GlobalGSKPharmaceuticalResearchRespiratory and PulmonaryUnited States

Positive results for Sanofi/Regeneron’s dupilumab in asthma

Positive results for Sanofi/Regeneron’s dupilumab in asthma

11-11-2014

French pharma major Sanofi and US partner Regeneron Pharmaceuticals have released positive results from…

dupilumabFrancePharmaceuticalRegeneron PharmaceuticalsResearchRespiratory and PulmonarySanofi

Vectura gets VR315 US development milestone

07-11-2014

UK inhaled therapies developer Vectura Group says that it has triggered a further milestone associated…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVectura GroupVR315

Janssen collaborating International Union Against Tuberculosis and Lung Disease on Sirturo study

Janssen collaborating International Union Against Tuberculosis and Lung Disease on Sirturo study

06-11-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary is to collaborate with the International…

bedaquilineJanssenPharmaceuticalResearchRespiratory and PulmonarySirturo

Boehringer Ingelheim's Spiriva Respimat NDA for asthma accepted for review by FDA

Boehringer Ingelheim's Spiriva Respimat NDA for asthma accepted for review by FDA

04-11-2014

German family-owned drug major Boehringer Ingelheim has had its Spiriva Respimat (tiotropium bromide)…

Boehringer IngelheimGermanyPharmaceuticalRegulationRespiratory and PulmonarySpirivaSpiriva Respimat

Almirall transfers rights to respiratory business to AstraZeneca

Almirall transfers rights to respiratory business to AstraZeneca

03-11-2014

Spanish pharma company Almirall has transferred the rights to its respiratory franchise to Anglo-Swedish…

AlmirallAstraZenecaEkliraPharmaceuticalResearchRespiratory and PulmonarySpain

India’s Cipla calls for revocation of Novartis’ Onbrez patents

01-11-2014

Indian drugmaker Cipla has asked the government to revoke five patents that Swiss pharma major Novartis…

CiplaIndiaMarkets & MarketingNovartisOnbrezPatentsPharmaceuticalRespiratory and PulmonaryUnibrez

Stallergenes furthers global expansion and opens affiliate in Ontario, Canada

Stallergenes furthers global expansion and opens affiliate in Ontario, Canada

24-10-2014

Stallergenes, a France-based global healthcare company specialized in diagnosis and treatment of allergies,…

CanadaMarkets & MarketingOralairPharmaceuticalRespiratory and PulmonaryStallergenes

IQWiG finds no added benefit for GSK’s Anoro Ellipta in COPD

21-10-2014

According to the findings of an early benefit assessment under the German Act on the Reform of the Market…

Anoro ElliptaGermanyGlaxoSmithKlinePharmaceuticalPricingRegulationRespiratory and Pulmonary

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

16-10-2014

The US Food and Drug Administration has approved Esbriet (pirfenidone), from Roche subsidiary Genentech,…

Boehringer IngelheimEsbrietGenentechnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

New Zealand approval of Novartis multiproduct proposal

10-10-2014

New Zealand’s Pharmaceutical Management Agency PHARMAC has announced the approval of an agreement with…

NeurologicalNew ZealandOncologyPharmaceuticalRegulationRespiratory and Pulmonary

Teva to drop 14 pipeline projects as it refocuses

Teva to drop 14 pipeline projects as it refocuses

07-10-2014

Israeli generics giant Teva Pharmaceutical Industries has concluded an extensive evaluation of its current…

CopaxoneIsraelManagementNeurologicalOncologyPharmaceuticalRespiratory and PulmonaryTevaWomen's Health

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

01-10-2014

German family-owned pharma major Boehringer Ingelheim is investing more than 100 million euros ($127…

Boehringer IngelheimGermanyMarkets & MarketingPharmaceuticalProductionRespimatRespiratory and PulmonarySpiriva RespimatUK

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

Sanofi and Regeneron's dupilumab meets all primary and secondary endpoints Phase IIa study

01-10-2014

French drug major Sanofi and US biotech company Regeneron's dupilumab has met all primary and secondary…

dupilumabFrancePharmaceuticalRegeneronResearchRespiratory and PulmonarySanofiUSA

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

Merck's entry into allergic rhinitis market will send total market value soaring by 2018, says GlobalData

30-09-2014

The US market for treatments of allergic rhinitis is set to see its value increase fourfold by 2018,…

GlobalDataGrastekMarkets & MarketingMerck & CoOralairPharmaceuticalRagwitekRespiratory and PulmonarySingulairUSA

Verona Pharma appoints Biresh Roy as chief financial officer

Verona Pharma appoints Biresh Roy as chief financial officer

30-09-2014

UK respiratory specialist Verona Pharma has appointed Biresh Roy as chief financial officer and member…

BoardroomPharmaceuticalRespiratory and PulmonaryUKVerona Pharma

Almirall’s aclidinium bromide/formoterol backed by EMA/CHMP to treat COPD

Almirall’s aclidinium bromide/formoterol backed by EMA/CHMP to treat COPD

26-09-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a…

aclidiniumAlmirallAstraZenecaBrimica GenuairDuaklir GenuairEuropeformoterolPharmaceuticalRegulationRespiratory and Pulmonary

Asthma’s treatment pipeline very strong as more personalized medicines emerge

Asthma’s treatment pipeline very strong as more personalized medicines emerge

26-09-2014

Asthma has a very strong drug pipeline, with almost 100 novel molecules or formulations currently in…

AstraZenecabenralizumabBosatriaCinquilGlaxoSmithKlineGlobalPharmaceuticalResearchRespiratory and PulmonaryTeva Pharmaceutical Industries

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

25-09-2014

German family-owned pharma major Boehringer Ingelheim Pharmaceuticals has received US Food and Drug Administration…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivaUSA

1 to 25 of 316 results

Back to top